NEW YORK, NY - Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic.
NEW YORK, NY - Memorial Sloan-Kettering Cancer Center has announced the gift of a membership interest in Geoffrey Beene, LLC, the company that controls the business and fashion empire created by legendary designer Geoffrey Beene.
NEW YORK, NY - New findings from a Decision Analysis for the US Preventative Services Task Force (USPSTF) suggest that routine colorectal cancer screenings can be stopped in patients over the age of 75.
NEW YORK, NY - Memorial Sloan-Kettering Cancer Center and Summit Medical Group together announce a new collaborative relationship for the care of people with cancer.
NEW YORK, NY - American tennis player and World No. 8 ranked James Blake will formally announce today the launch of the Thomas Blake, Sr., Memorial Research Fund, which he established to support cancer research at Memorial Sloan-Kettering Cancer Center.
NEW YORK, NY - New data from a randomized, controlled trial found that acupuncture provided significant reductions in pain, dysfunction, and dry mouth in head and neck cancer patients after neck dissection.
NEW YORK, NY - New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments.
NEW YORK, NY - A study led by researchers at Memorial Sloan-Kettering Cancer Center has uncovered how breast tumors use a particular type of molecule to promote metastasis - the spread of cancer cells.
NEW YORK, NY - Research led by investigators at Memorial Sloan-Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
NEW YORK, NY - The recent marketing of "at home" genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC).
NEW YORK - A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.
NEW YORK, NY - An international group of investigators led by scientists at Memorial Sloan-Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.
NEW YORK, NY - A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
NEW YORK, NY - A single prostate specific antigen (PSA) test taken before the age of 50 can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a new study published by researchers at Memorial Sloan-Kettering Cancer Center in New York and Lund University in Sweden.
NEW YORK, NY - The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan-Kettering Cancer Center is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers.
NEW YORK, NY - A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan-Kettering's new Brain Tumor Center (BTC).
NEW YORK, NY - Researchers have identified a specific group of microRNA molecules that are responsible for controlling genes that cause breast cancer metastasis.
NEW YORK, NY - Breast cancer risk varies widely among women who are carriers of the BRCA1 and BRCA2 mutations, according to a new study published in the January 9, 2008, issue of the Journal of the American Medical Association (JAMA).
New York, NY - A new study by researchers at Memorial Sloan-Kettering Cancer Center finds that even the sickest cancer patients are willing and able to "self-report" symptoms using the Internet, thus supplying key data in real time to their healthcare providers.
NEW YORK, NY - Three young investigators who have made major accomplishments in cancer research will be the recipients of the 2007 Paul Marks Prize for Cancer Research and will share a $150,000 award, announced Memorial Sloan-Kettering Cancer Center (MSKCC).
NEW YORK, NY - According to a new study published online today in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.
CHICAGO - A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive.
CHICAGO - Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
NEW YORK - The Bright Horizons Foundation for Children, Memorial Sloan-Kettering Cancer Center (MSKCC), Abyssinian Development Corporation (ADC), and Community Playthings today cut ribbons to officially open Harlem's first Bright Space center for homeless children at Abyssinian House, a Tier II transitional residence serving the families of Harlem.
NEW YORK - philanthropist and art collector Iris Cantor has made a major commitment to Memorial Sloan-Kettering Cancer Center to create an endowed chair for a senior researcher in the field of digestive cancers.
NEW YORK - Patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.
NEW YORK - Biologists at Memorial Sloan-Kettering Cancer Center have identified a set of genes expressed in human breast cancer cells that work together to remodel the network of blood vessels at the site of the primary tumor.
NEW YORK - A newly published study demonstrates that imaging with Positron Emission Tomography (PET) using a radiolabeled antibody accurately identifies whether a patient has clear cell renal carcinoma - the most common and aggressive type of renal tumor - and arms the urologist with crucial information that will help determine whether surgery is needed.
NEW YORK - The first report of an international study looking at CT to screen current or former smokers for lung cancer found that screening did not reduce deaths from lung cancer.
NEW YORK - Nominations are currently being sought for the Paul Marks Prize for Cancer Research. This award, established by Memorial Sloan-Kettering Cancer Center (MSKCC) in 2001, is named for Paul A. Marks, MD, President Emeritus of the Center and a distinguished scientist.
QUEENS, NY - The Queens Library HealthLink initiative was developed to place libraries at the center of an innovative new effort designed to help medically underserved communities throughout Queens access free cancer information, early detection screenings, cancer treatment resources, and other life-saving services.
NEW YORK - Researchers led by scientists at Memorial Sloan-Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of PTEN function. The findings from two related studies are published in the January 12 issue of Cell.
NEW YORK - Newly published results from a randomized, Phase III trial show that the drug sunitinib malate (Sutent®) is more effective than the conventional treatment given as an initial therapy for patients with advanced kidney cancer.
NEW YORK - Computational biology researchers today announced a new Internet tool for the exploration of the scientific literature in medicine and biology. The freely accessible iHOP service provides fast, accurate, comprehensive, and up-to-date summary information on more than 80,000 biological molecules by automatically extracting key sentences from millions of PubMed documents when a search is requested.
NEW YORK - Jacqueline Barnes, RN, MPH, of Memorial Sloan-Kettering Cancer Center and a resident of Roosevelt Island, NY, has been recognized for outstanding patient care with a New York Times Job Market "Tribute to Nurses" award.
NEW YORK - Memorial Sloan-Kettering Cancer Center is one of six leading institutions that will share in a $120 million gift from a foundation created by American billionaire Daniel K. Ludwig.
NEW YORK - Almost three-fourths of pediatric cancer survivors will have a chronic health problem within 30 years after the cancer diagnosis, with 40 percent experiencing a serious, life-threatening, disabling, or fatal condition, according to investigators from Memorial Sloan-Kettering Cancer Center (MSKCC), St. Jude Children's Research Hospital, and other institutions.
NEW YORK - A gift from the estate of renowned fashion designer Geoffrey Beene will enable MSKCC to launch an ambitious research initiative to be known as the Geoffrey Beene Cancer Research Center.
NEW YORK - Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years.
NEW YORK - The Starr Foundation today announced that it has made a $100 million grant to create a wide-ranging cancer consortium to coordinate the efforts of five internationally renowned research institutions in the fight against cancer. Joining this ambitious undertaking are The Broad Institute of MIT and Harvard, Cold Spring Harbor Laboratory, Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College.
NEW YORK - Memorial Sloan-Kettering Cancer Center (MSKCC) is now poised to take greater advantage of a new era in cancer research and education with the opening of a state-of-the-art research center, the establishment of a new graduate school, and the founding of a novel research program in human oncology.
BASKING RIDGE, NJ - Memorial Sloan-Kettering Cancer Center (MSKCC) opened a new state-of-the-art outpatient cancer treatment facility in Basking Ridge, New Jersey, today. The new 85,000-square-foot facility incorporates the latest concepts in therapeutic design and offers the most advanced cancer care services.
NEW YORK - A retrospective study by urologists at MSKCC and their colleagues, suggests that this practice needs to be re-evaluated. Researchers add that with advances in imaging, almost 70 percent of kidney cancer patients have their tumor detected at a very small size allowing surgeons to perform less radical surgery with superior results.
NEW YORK - The Tri-Institutional Stem Cell Initiative, comprised of three leading New York City biomedical research institutions -- Memorial Sloan-Kettering Cancer Center, The Rockefeller University, and Weill Medical College of Cornell University -- has announced the first wave of stem cell research projects to be funded through a $50 million gift from The Starr Foundation.
NEW YORK - Memorial Sloan-Kettering Cancer Center (MSKCC) has opened a new 72,000-square-foot surgical center that was uniquely designed to take advantage of the latest medical technology while enhancing patient safety and efficiency of care.
ATLANTA - A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation. The results of the study, which are being presented today at the annual American Society of Clinical Oncology meeting, also provide the strongest evidence to date that this surgery significantly reduces the overall risk of BRCA-associated breast and ovarian cancers.
ATLANTA - According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.
NEW YORK - Memorial Sloan-Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan-Kettering's new cancer research facility, including a 23-story laboratory structure that opens this month. Mr. Zuckerman's donation is the largest single commitment by an individual in Memorial Sloan-Kettering's history.
NEW YORK - The New York Yankees and Memorial Sloan-Kettering Cancer Center have announced a new and unprecedented initiative to raise funds to help support research and treatment for children with cancer.
NEW YORK - Scientists have uncovered new information about what orchestrates the complex balance between blood stem cells and mature blood cells, a relationship that is often disrupted in leukemia. The results will lead to a better understanding of the behavior of leukemic cells and may have vital clinical applications for patients recovering from chemotherapy, radiation therapy, or bone marrow transplantation.
NEW YORK - A multi-institutional study led by Memorial Sloan-Kettering Cancer Center (MSKCC) shows that patients whose colorectal cancer has spread to the liver and who received chemotherapy directly to the liver through a pump in the abdomen (an approach called Hepatic Arterial Infusion or HAI) fare better than those who received systemic (intravenously administered) chemotherapy.
NEW YORK - Women with Stage III ovarian cancer when treated with a combination of intravenous (IV) and intra-abdominal chemotherapy, following the successful surgical removal of tumors, survived almost a year longer than those who received IV chemotherapy alone.
